全文获取类型
收费全文 | 21579篇 |
免费 | 1261篇 |
国内免费 | 164篇 |
专业分类
耳鼻咽喉 | 86篇 |
儿科学 | 269篇 |
妇产科学 | 150篇 |
基础医学 | 853篇 |
口腔科学 | 178篇 |
临床医学 | 4759篇 |
内科学 | 2934篇 |
皮肤病学 | 88篇 |
神经病学 | 753篇 |
特种医学 | 277篇 |
外科学 | 2076篇 |
综合类 | 3627篇 |
一般理论 | 1篇 |
预防医学 | 3288篇 |
眼科学 | 56篇 |
药学 | 2179篇 |
30篇 | |
中国医学 | 483篇 |
肿瘤学 | 917篇 |
出版年
2024年 | 42篇 |
2023年 | 438篇 |
2022年 | 946篇 |
2021年 | 1187篇 |
2020年 | 1021篇 |
2019年 | 1115篇 |
2018年 | 1133篇 |
2017年 | 830篇 |
2016年 | 902篇 |
2015年 | 910篇 |
2014年 | 2280篇 |
2013年 | 2018篇 |
2012年 | 1857篇 |
2011年 | 1880篇 |
2010年 | 1339篇 |
2009年 | 935篇 |
2008年 | 690篇 |
2007年 | 575篇 |
2006年 | 452篇 |
2005年 | 399篇 |
2004年 | 320篇 |
2003年 | 244篇 |
2002年 | 223篇 |
2001年 | 186篇 |
2000年 | 164篇 |
1999年 | 125篇 |
1998年 | 116篇 |
1997年 | 67篇 |
1996年 | 58篇 |
1995年 | 59篇 |
1994年 | 57篇 |
1993年 | 54篇 |
1992年 | 35篇 |
1991年 | 31篇 |
1990年 | 31篇 |
1989年 | 16篇 |
1988年 | 21篇 |
1987年 | 13篇 |
1986年 | 9篇 |
1985年 | 46篇 |
1984年 | 48篇 |
1983年 | 23篇 |
1982年 | 22篇 |
1981年 | 18篇 |
1980年 | 19篇 |
1979年 | 15篇 |
1978年 | 7篇 |
1977年 | 9篇 |
1976年 | 8篇 |
1972年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
《Neuro-Chirurgie》2022,68(3):262-266
BackgroundThe prognosis for patients with recurrent glioblastoma (GBM) is dismal, and the question of repeat surgery at time of recurrence is common. Re-operation in the management of these patients remains controversial, as there is no randomized evidence of benefit. An all-inclusive pragmatic care trial is needed to evaluate the role of repeat resection.Methods3rGBM is a multicenter, pragmatic, prospective, parallel-group randomized care trial, with 1:1 allocation to repeat resection or standard care with no repeat resection. To test the hypothesis that repeat resection can improve overall survival by at least 3 months (from 6 to 9 months), 250 adult patients with prior resection of pathology-proven glioblastoma for whom the attending surgeon believes repeat resection may improve quality survival will be enrolled. A surrogate measure of quality of life, the number of days outside of hospital/nursing/palliative care facility, will also be compared. Centers are invited to participate without financial compensation and without contracts. Clinicians may apply to local authorities to approve an investigator-led in-house trial, using a common protocol, web-based randomization platform, and simple standardized case report forms.DiscussionThe 3rGBM trial is a modern transparent care research framework with no additional risks, tests, or visits other than what patients would encounter in normal care. The burden of proof remains on repeat surgical management of recurrent GBM, because this management has yet to be shown beneficial. The trial is designed to help patients and surgeons manage the uncertainty regarding optimal care.Clinical Trial Registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT04838782. 相似文献
7.
8.
《Drug metabolism and pharmacokinetics》2020,35(6):563-570
Minesapride is a novel 5-hydroxytryptamine 4 (5-HT4) receptor partial agonist that is expected to show efficacy in patients with irritable bowel syndrome with predominant constipation and functional constipation. An open-label study was conducted to evaluate pharmacokinetics (PK) and safety of minesapride. Japanese subjects, 12 elderly and 12 young, received a single oral dose of minesapride 40 mg/day in the fasted state. Metabolite profiles were also investigated in this clinical study and in an in vitro study using cryopreserved hepatocytes. Clinical results showed that minesapride was rapidly absorbed (Cmax: 2302.1 ng/mL in the elderly group, 2117.5 ng/mL in the young group), and the plasma concentration then decreased with half-life of approximately 7 h. There were no notable PK differences between elderly and young groups. No serious adverse events (AEs) were observed. The only AE that occurred in 2 or more subjects was diarrhea. Metabolite profiles in plasma and urine were similar between elderly and young groups. No major metabolites exceeded 10% of unchanged minesapride, and results of the in vitro study suggested that there were no human-specific metabolites. From the viewpoints of PK and metabolite profiling, no dose adjustment of minesapride is warranted in elderly population without renal or hepatic impairment. 相似文献
9.
目的:研究全麻复合硬膜外在高龄患者腹腔镜直肠癌根治术中的应用效果。方法:选择60岁以上择期行腹腔镜直肠癌根治术患者60例,随机分为G组和GA组,每组各30例。G组患者为单纯全麻组,GA组患者为硬膜外复合全麻组。GA组患者在诱导前取L1~2硬膜外穿刺置管,予0.5%罗哌卡因5 ml,术中每小时追加5~7 ml。两组患者诱导方法相同:即,咪哒唑仑0.04 mg/kg、舒芬太尼0.3~0.4μg/kg、顺阿曲库铵0.15~0.20 mg/kg、依托咪酯0.2~0.3 mg/kg。监测并记录患者血压(BP),心率(HR),心电图(ECG),术中全麻药用量及术后患者苏醒情况。结果:GA组患者气腹后、拔管前BP、HR明显低于G组(P<0.05),且全麻药用量明显低于G组(P<0.05)。结论:全麻复合硬膜外应用于老年腹腔镜直肠癌手术较单纯全麻用药量减少,术中循环更加稳定,是腹腔镜直肠癌根治术比较安全可行的麻醉方法。 相似文献
10.
ObjectiveThe purpose of this paper is to review the efficacy and safety profile in children treated with topical 0.03% Tacrolimus ointment for vernal keratoconjunctivitis in Middle East and to propose a treatment posology. According to recent studies, a complex non-IgE dependent mechanism plays a relevant role in the pathogenesis of vernal keratoconjunctivitis. Numerous cells and mediators have been found in the serum, conjunctiva and tears of patients with Vernal keratoconjunctivitis.DesignThis case series included 10 patients from a single centre, pediatric department of a tertiary hospital with active symptomatic vernal keratoconjunctivitis. All the patients had proliferative lesions and corneal involvement despite conventional medications, including topical steroids. All other medications, systemic and topical: steroids, antihistamines and cyclosporine, were unsuccessful. Patients were treated with topical 0.03% Tacrolimus ointment twice daily for 8 weeks and then once a day for the next two month followed by thrice a week for two months. The changes in symptoms and signs after treatment were evaluated, also the development of possible complications was assessed.ResultsThe results showed a significant reduction in signs and symptoms after 4 weeks of the treatment. Clinical resolution of giant papillae and corneal lesions were seen within eight weeks and no additional drug was required during that period, except tear substitutes. Treatment was continued for period of two months and then slowly reduced.ConclusionThe use of 0.03% Tacrolimus ointment is safe and effective in children refractory to conventional treatment of vernal keratoconjunctivitis even in high temperature climate as Middle East. Due to the effectiveness of the treatment, the dosage used may be proposed for conventional use. 相似文献